Magrolimab has been at the forefront of drugs targeting CD47, a protein expressed on cancer cells that sends out a ‘don’t eat me’ signal to macrophage cells of the immune system, and was the ...

The $4.9 billion acquisition of Forty Seven by Gilead is an example of the explosive excitement and investment into macrophage-directed therapies, utilizing CD47 checkpoint blockades ...

IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47–SIRPα interaction in order to promote the phagocytosis of cancer cells by macrophages. It binds to human CD47 with ...

IMC-002 is a fully human IgG monoclonal antibody designed to block CD47–SIRP-α interaction in order to promote the phagocytosis of cancer cells by macrophages. It binds to human CD47 with an ...